Mei-Ching Liu

8.1k total citations · 2 hit papers
9 papers, 3.0k citations indexed

About

Mei-Ching Liu is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Mei-Ching Liu has authored 9 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Cancer Research. Recurrent topics in Mei-Ching Liu's work include HER2/EGFR in Cancer Research (4 papers), Breast Cancer Treatment Studies (3 papers) and Colorectal Cancer Screening and Detection (3 papers). Mei-Ching Liu is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Breast Cancer Treatment Studies (3 papers) and Colorectal Cancer Screening and Detection (3 papers). Mei-Ching Liu collaborates with scholars based in Taiwan, Canada and Italy. Mei-Ching Liu's co-authors include Tadeusz Pieńkowski, Pinuccia Valagussa, Luca Gianni, Young‐Hyuck Im, Giulia Bianchi, Ling‐Ming Tseng, Juan de la Haba-Rodríguez, Brigitte Poirier, Vichien Srimuninnimit and Paolo Morandi and has published in prestigious journals such as The Lancet Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Surgical Oncology.

In The Last Decade

Mei-Ching Liu

9 papers receiving 3.0k citations

Hit Papers

Efficacy and safety of ne... 2011 2026 2016 2021 2011 2016 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    2011 1.5k citations Luca Gianni, Tadeusz Pieńkowski et al. The Lancet Oncology profile →
  2. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
    2016 555 citations Luca Gianni, Tadeusz Pieńkowski et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mei-Ching Liu Taiwan 9 2.5k 1.3k 873 519 370 9 3.0k
Yasuaki Sagara Japan 25 1.8k 0.7× 1.2k 0.9× 669 0.8× 656 1.3× 342 0.9× 109 2.9k
Debra Frye United States 20 2.5k 1.0× 1.7k 1.2× 485 0.6× 380 0.7× 198 0.5× 36 3.2k
Juan de la Haba-Rodríguez Spain 23 3.1k 1.2× 1.8k 1.4× 970 1.1× 1.0k 2.0× 161 0.4× 127 4.0k
G. N. Hortobágyi United States 23 1.7k 0.7× 962 0.7× 253 0.3× 543 1.0× 154 0.4× 106 2.7k
Ulrike Nitz Germany 22 1.5k 0.6× 1.1k 0.9× 331 0.4× 469 0.9× 114 0.3× 135 2.4k
Binghe Xu China 26 2.4k 0.9× 1000 0.8× 482 0.6× 1.0k 1.9× 126 0.3× 149 3.1k
In Ae Park South Korea 28 1.1k 0.4× 1.1k 0.8× 480 0.5× 310 0.6× 352 1.0× 72 2.6k
Heather L. McArthur United States 28 1.8k 0.7× 800 0.6× 598 0.7× 611 1.2× 135 0.4× 146 2.7k
Carl‐Magnus Rudenstam Sweden 20 1.7k 0.7× 954 0.7× 511 0.6× 293 0.6× 350 0.9× 35 2.5k
Jennifer Eng‐Wong United States 20 1.5k 0.6× 647 0.5× 418 0.5× 711 1.4× 152 0.4× 59 2.0k

Countries citing papers authored by Mei-Ching Liu

Since Specialization
Citations

This map shows the geographic impact of Mei-Ching Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei-Ching Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei-Ching Liu more than expected).

Fields of papers citing papers by Mei-Ching Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei-Ching Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei-Ching Liu. The network helps show where Mei-Ching Liu may publish in the future.

Co-authorship network of co-authors of Mei-Ching Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Mei-Ching Liu. A scholar is included among the top collaborators of Mei-Ching Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei-Ching Liu. Mei-Ching Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
2.
Gianni, Luca, Tadeusz Pieńkowski, Young‐Hyuck Im, et al.. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet Oncology. 17(6). 791–800. 555 indexed citations breakdown →
3.
4.
Gianni, Luca, Tadeusz Pieńkowski, Young‐Hyuck Im, et al.. (2011). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 13(1). 25–32. 1535 indexed citations breakdown →
5.
Kuo, Li‐Jen, Mei-Ching Liu, James Jer‐Min Jian, et al.. (2007). Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy?. Annals of Surgical Oncology. 14(10). 2766–2772. 141 indexed citations
6.
Hortobágyi, Gabriel N., Jaime de Salazar, Kathleen I. Pritchard, et al.. (2005). The Global Breast Cancer Burden: Variations in Epidemiology and Survival. Clinical Breast Cancer. 6(5). 391–401. 465 indexed citations
7.
Kuo, Li‐Jen, Mei-Hua Tsou, Mei-Ching Liu, et al.. (2004). Interpretation of Magnetic Resonance Imaging for Locally Advanced Rectal Carcinoma After Preoperative Chemoradiation Therapy. Diseases of the Colon & Rectum. 48(1). 23–28. 136 indexed citations
8.
Kuo, Li‐Jen, et al.. (2003). How aggressive should we be in patients with stage iv colorectal cancer?. Diseases of the Colon & Rectum. 46(12). 1646–1652. 43 indexed citations
9.
Cheng, Jason Chia‐Hsien, Mei-Ching Liu, Mei-Hua Tsou, et al.. (2002). Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 52(4). 980–988. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuaki Sagara Breakdown of academic impact, for papers by Debra Frye Breakdown of academic impact, for papers by Juan de la Haba-Rodríguez Breakdown of academic impact, for papers by G. N. Hortobágyi Breakdown of academic impact, for papers by Ulrike Nitz Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by Heather L. McArthur Breakdown of academic impact, for papers by Carl‐Magnus Rudenstam Breakdown of academic impact, for papers by Jennifer Eng‐Wong
Rankless by CCL
2026